The Gut Microbiota, Inflammation and Cardiovascular Disease in HIV-InfectedIndividuals.

HIV 感染者的肠道微生物群、炎症和心血管疾病。

• 批准号: 10463677
• 负责人: TECLA MTUI TEMU
• 金额: $ 16.86万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-25 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10463677
• 关键词: Acquired Immunodeficiency Syndrome; Adult; Africa; Africa South of the Sahara; African; Age; Atherosclerosis; Bacteria; Bacterial Infections; Blood specimen; Body mass index; CD4 Positive T Lymphocytes; Cardiovascular Diseases; Cardiovascular system; Categories; Cell Count; Characteristics; Chronic; Clinical; Clinical Research; Collaborations; Communities; Consensus; Cotrimoxazole; Country; Creativeness; Cross-Sectional Studies; Cytomegalovirus; Data; Development; Diabetes Mellitus; Diet; Disadvantaged; Enrollment; Environment; Ethnic Origin; Europe; Exposure to; Five-Year Plans; Funding; Future; General Population; Geography; Goals; HIV; HIV Infections; HIV Seropositivity; Health; Helminths; Immunology; Income; Individual; Inflammation; Inflammatory Response; International; Intervention; Kenya; Laboratory Research; Link; Malaria; Measures; Mentors; Metabolic Diseases; Metabolic syndrome; Methods; Morbidity - disease rate; Mucous Membrane; Parasitic infection; Participant; Pathogenesis; Patient Recruitments; Patients; Persons; Phylogenetic Analysis; Physicians; Population; Positioning Attribute; Prevalence; Preventive; Productivity; RNA; Race; Reporting; Research; Research Design; Research Personnel; Research Training; Resource-limited setting; Resources; Risk; Risk Assessment; Risk Factors; Role; Scientist; Secondary to; Source; Therapeutic; Training; Treatment outcome; Tuberculosis; Underserved Population; United States National Institutes of Health; Universities; Washington; Water; Woman; antiretroviral therapy; biological specimen archives; cardiovascular disorder risk; career; carotid intima-media thickness; chronic inflammatory disease; co-infection; cohort; dietary; dysbiosis; experience; gastrointestinal; gastrointestinal epithelium; geographic difference; global health; gut bacteria; gut dysbiosis; gut microbiome; gut microbiota; immune activation; improved; innovation; men; microbial; microbiome; microbiome research; microbiota profiles; mortality; pathogenic bacteria; pre-clinical; prevent; professor; programs; sample collection; skills; stool sample; success; supportive environment; systemic inflammatory response

PROJECT SUMMARY/ABSTRACT The global burden of HIV associated cardiovascular disease (CVD) has tripled over the last two decades with the majority of the burden experienced in sub-Saharan Africa (SSA). Reducing the burden of CVD in this population will require a firm understanding of region-specific risk factors, particularly those known to modulate the inflammatory response involved in CVD. Although alteration of the gut bacteria communities (dysbiosis) has been linked to CVD in healthy adults, the role of gut dysbiosis on CVD risk is not well investigated among HIV-infected patients receiving suppressive ART. This K01 proposal details a five-year plan to provide the candidate, Dr. Tecla Temu, with the training and expertise needed to evaluate the relationship between gut dysbiosis and markers of early CVD in an established cohort of HIV-infected adults enrolled in the Kenya HIV- CVD study (R21 TW010459; PI: Farquhar). Taking advantage of stool specimens, archived blood samples, extensive data on HIV-infection related factors, co-infections (latent TB, helminths), and measures of early atherosclerotic disease (carotid intima media thickness) and metabolic disease in the Kenya HIV-CVD study, this project proposes to 1) characterize gut microbiota of HIV-infected adults in SSA and 2) determine the relationship of gut microbiota with measures of inflammation and subclinical CVD. Dr. Temu's long-term goal is to be a successful physician-scientist and independent investigator focused on understanding the pathogenesis of HIV-associated CVD in resource-limited settings. She aims to develop new preventive and therapeutic methods that will improve the health of disadvantaged, underserved populations in SSA and globally. The proposed program will build on the candidate's extensive experience with international clinical and laboratory research and improve her skills in cardiovascular research, specifically study design, as well as analysis and interpretation of microbiome data, and HIV mucosal immunology. Dr. Temu has strong institutional support from the University of Washington's Department of Global Health where she is currently a Clinical Assistant Professor. Her training plan incorporates an outstanding mentoring environment, one that includes experts in HIV, cardiovascular disease, and gut microbiome research in SSA, and it leverages more than 30 years of Fogarty-funded research and training collaborations between the University of Washington and University of Nairobi. This highly supportive environment will enable Dr. Temu to not only accomplish her proposed research and training goals and successfully position herself for an independent research career, but also allow her to achieve her full potential for productivity and creativity as a physician-scientist in the UW Department of Global Health.

项目概要/摘要 过去二十年里，艾滋病毒相关心血管疾病（CVD）的全球负担增加了两倍 撒哈拉以南非洲地区（SSA）经历了大部分负担。减轻CVD负担 人口需要对特定地区的风险因素有深入的了解，特别是那些已知会调节的因素 CVD 中涉及的炎症反应。尽管肠道细菌群落发生改变（菌群失调） 肠道菌群失调与健康成年人的 CVD 相关，但肠道菌群失调对 CVD 风险的作用尚未得到充分研究 接受抑制性 ART 的 HIV 感染患者。该 K01 提案详细介绍了一个五年计划，旨在提供 候选人 Tecla Temu 博士拥有评估肠道与肠道之间关系所需的培训和专业知识 肯尼亚艾滋病毒研究中心登记的艾滋病毒感染成年人队列中的菌群失调和早期心血管疾病标志物 CVD 研究（R21 TW010459；PI：Farquhar）。利用粪便标本、存档的血液样本， 关于 HIV 感染相关因素、合并感染（潜伏性结核病、蠕虫）以及早期预防措施的大量数据 肯尼亚 HIV-CVD 研究中的动脉粥样硬化性疾病（颈动脉内膜中层厚度）和代谢性疾病， 该项目建议 1) 描述 SSA 中 HIV 感染成人的肠道微生物群特征，以及 2) 确定 肠道微生物群与炎症和亚临床心血管疾病指标的关系。 Temu博士的长期目标 是成为一名成功的医师科学家和独立研究者，专注于了解 资源有限环境中 HIV 相关 CVD 的发病机制。她的目标是开发新的预防和 改善 SSA 和服务不足的弱势群体健康的治疗方法 全球。拟议的计划将建立在候选人在国际临床方面的丰富经验的基础上 和实验室研究，并提高她在心血管研究方面的技能，特别是研究设计，以及 微生物组数据的分析和解释以及艾滋病毒粘膜免疫学。 Temu博士有很强的 她目前是华盛顿大学全球健康系的机构支持 临床助理教授。她的培训计划包含了出色的指导环境， SSA 包括艾滋病毒、心血管疾病和肠道微生物组研究方面的专家，并且它利用了更多 福格蒂资助的华盛顿大学之间超过 30 年的研究和培训合作 和内罗毕大学。这种高度支持的环境将使 Temu 博士不仅能够实现她的目标 提出了研究和培训目标，并成功地为自己的独立研究生涯定位，但是 也让她能够充分发挥作为华盛顿大学医学科学家的生产力和创造力的潜力 全球卫生部。

项目成果

Oral Pre-Exposure Prophylaxis (PrEP) Awareness and Acceptability Among Persons who Inject Drugs (PWID) in Kenya: A Qualitative Investigation.

肯尼亚注射毒品者 (PWID) 的口服暴露前预防 (PrEP) 意识和接受度：定性调查。

• 发表时间: 2023-02-22
• 作者: Cosmas, Mugambi;Loice, Mbogo;William, Sinkele;Esther, Gitau;Carey, Farquhar;Tecla, Temu;David, Bukusi;John, Kinuthia;Aliza, Monroe
• 通讯作者: Aliza, Monroe

Descriptive study: Feasibility of integrating hypertension screening into HIV assisted partner notification services model in Kenya.

描述性研究：将高血压筛查纳入肯尼亚艾滋病毒辅助伴侣通知服务模式的可行性。

• 发表时间: 2023-02-22
• 影响因子: 1.6
• 作者: Mogaka, Jerusha N;Lagat, Harrison;Otieno, George;Macharia, Paul;Wamuti, Beatrice;Masyuko, Sarah;Sharma, Monisha;Kariithi, Edward;Farquhar, Carey;Temu, Tecla M
• 通讯作者: Temu, Tecla M